Conatumumab  (Synonyms: AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody)

Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (K_d: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. ^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IC50: DR5 (<1 nM)^[2]

Conatumumab (0-10 μg/mL, 4 h) activates caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells^[2].
Conatumumab (0-10 μg/mL, 24 h) reduces cell viability in sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors^[2].
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145.65 (kDa)

896731-82-1

Liquid

Colorless to light yellow

[Conatumumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91.  [Content Brief]

  [2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.  [Content Brief]